OPRM1 rs1799858: Opioid Receptor Signaling and Pain Relief
The rs1799858 single nucleotide polymorphism, commonly known as A118G or Asn40Asp, is a well-studied missense variant in the mu-opioid receptor gene (OPRM1). It alters the structure of the mu-opioid receptor, which is the primary binding target for both endogenous endorphins and opioid analgesic medications like morphine and hydromorphone. Clinical and laboratory studies link this genetic change to subtle differences in pain perception, opioid analgesic dose requirements, and side effect profiles, although current pharmacogenomic evidence remains limited and mixed.
What each genotype means
Typical opioid response
You carry two copies of the common A allele, which encodes the canonical mu-opioid receptor. Clinical research generally links this genotype with typical analgesic sensitivity to opioid medications such as morphine, fentanyl, and hydromorphone. Because response can vary widely based on individual clinical factors, discuss any pain management dosing questions directly with your healthcare provider or pharmacist.
Carried by approximately 70% to 80% of individuals of European descent and over 95% of individuals of African descent, but found in only about 20% to 40% of East Asian populations.
Moderately altered opioid sensitivity
You carry one copy of the A118G (G) variant allele, which is associated with altered cell-surface receptor binding and expression. Some clinical studies suggest individuals with this genotype may require modestly higher doses of certain opioid agonists to achieve effective pain relief or exhibit different sensitivity to opioid antagonists like naltrexone, though evidence across various populations remains mixed. Always consult your prescribing clinician or pharmacist regarding opioid dosing and therapeutic monitoring.
Present in roughly 20% to 25% of individuals of European ancestry and approximately 40% to 50% of individuals of East Asian ancestry, while occurring in under 5% of individuals of African ancestry.
Reduced opioid sensitivity
You carry two copies of the G variant allele, which produces the Asn40Asp amino acid change in the mu-opioid receptor. Published research and meta-analyses suggest that individuals with the homozygous GG genotype often require higher doses of opioid analgesics to achieve adequate pain management, though clinical findings vary by specific opioid and study population. Do not alter any prescribed medications on your own; consult your physician or pharmacist regarding tailored dosing and monitoring.
Carried by only about 1% to 3% of individuals of European ancestry and less than 1% of African populations, but found in approximately 10% to 20% of East Asian populations.
Genetic Location and Molecular Impact
The single nucleotide polymorphism rs1799858 is located in exon 1 of the OPRM1 gene on chromosome 6. In scientific literature, it is traditionally designated as A118G or c.118A>G, which causes an amino acid substitution from asparagine to aspartic acid at position 40 (Asn40Asp) of the extracellular domain of the mu-opioid receptor. The OPRM1 gene provides instructions for manufacturing the primary receptor responsible for mediating pain suppression, reward pathways, and physiological responses to both natural endorphins and synthetic opioids. Laboratory studies suggest that the substitution introduced by the minor G allele can lead to altered receptor density, differences in receptor glycosylation, or reduced intracellular signaling compared to the standard A allele. Despite its clear cellular impact in experimental settings, the overall physiological outcome in living humans varies significantly across different clinical contexts and environmental settings.
Pharmacogenomic Associations and Pain Response
A substantial body of research has examined whether rs1799858 status influences the effectiveness of pain medications such as morphine, fentanyl, oxycodone, and hydromorphone. Many clinical studies suggest that individuals carrying one or two copies of the G allele may require higher therapeutic doses of opioids to achieve satisfactory analgesia following surgery or during cancer treatment. Carriers have also been observed in some studies to experience different rates of opioid-induced side effects, such as a lower incidence of opioid-induced itching (pruritus). Additionally, researchers have examined subjective drug effects, noting that G allele carriers might report altered feelings of sedation or reward after opioid administration. However, because multiple clinical trials have failed to replicate these analgesic dose associations or have found contradictory results, professional bodies treat the pharmacogenomic evidence for clinical dosing changes as limited and exploratory.
Evidence Strength and Clinical Reality
While rs1799858 is among the most heavily investigated variants in pain pharmacogenetics, the overall clinical evidence remains classified as limited and inconsistent. Major clinical guidelines, such as those from the Clinical Pharmacogenetics Implementation Consortium (CPIC), do not currently recommend altering clinical opioid dosing solely based on rs1799858 genotype. Real-world pain relief is a complex, multigenic trait influenced by liver enzymes that metabolize medications (such as CYP2D6), other pain-signaling proteins (such as COMT), and diverse patient factors including age, psychological state, and underlying health conditions. Furthermore, research attempting to connect rs1799858 to risk for opioid dependence or alcohol use disorder has yielded mixed outcomes, showing modest associations in some ethnic cohorts that fail to replicate in others. Consequently, rs1799858 is not a standalone diagnostic marker.
What You Can and Cannot Do With Your Results
Knowing your rs1799858 genotype offers an educational glimpse into the biology of your opioid receptors, but it cannot accurately predict how you will respond to a specific pain medication. You should never alter, increase, or discontinue any prescribed pain management regimen based on direct-to-consumer genetic data or self-interpreted genotypes. Doing so can cause uncontrolled pain, sudden withdrawal symptoms, or accidental overdose. If you anticipate surgery or require chronic pain management, you may share your genetic profile with your clinician or clinical pharmacist as part of a broader health conversation. Health professionals evaluate drug choices through validated clinical indicators, personal medical history, drug-drug interactions, and close monitoring rather than isolated genetic variants.
How common is this variant?
The minor G allele shows wide variation worldwide; its frequency is approximately 1.5% to 4% in individuals of African ancestry, 10% to 15% in Europeans, and commonly exceeds 35% to 45% in East Asian populations.
Frequently asked questions
Does having the G allele make me immune to opioid pain relievers?
No, carrying the G allele does not make you immune to opioid analgesics. While some studies suggest G carriers may need modestly higher doses to reach comparable pain relief, opioids remain effective pain medications across all genotypes.
Can rs1799858 predict if I will become addicted to opioids?
No, rs1799858 cannot predict whether an individual will develop an addiction. Research investigating OPRM1 variants and substance use disorders has produced conflicting and inconclusive results, showing that addiction risk is shaped by complex behavioral, social, and polygenic factors.
Should my doctor change my prescription based on this SNP?
Currently, pharmacogenetic guidelines do not recommend prescribing different opioid doses based solely on rs1799858. Standard medical practice relies on individualized clinical evaluation, starting at appropriate baseline doses and adjusting based on direct patient feedback.
Is rs1799858 the same thing as OPRM1 A118G?
Yes, rs1799858 is the official dbSNP database identifier for the A118G genetic variation. In academic research, it is often interchangeably cited as c.118A>G, Asn40Asp, or N40D.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1799858?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29